case_images: PMC10995231_01
case_images: Patient's timeline.
case_images: fimmu-15-1375497-g001.jpg
case_images: PMC10995231_01_fimmu-15-1375497-g001.jpg
case_images: f1
case_images: In July 2022 ( Figure 1 : patient's timeline), he consulted in our center (Paoli-Calmettes Institute, Cancer Center in Marseille, France) and beneficiated from a right inguinal lymph node biopsy (July 22, 2022).
case_images: PET-CT at baseline (A), after 3 Ipilimumab/Nivolumab combinations (B) and after 3 Nivolumab maintenance (C).
case_images: fimmu-15-1375497-g002.jpg
case_images: PMC10995231_01_fimmu-15-1375497-g002.jpg
case_images: f2
case_images: Unfortunately, in April 2023, after only 6 months of adjuvant pembrolizumab the patient relapsed with multiple metastatic liver lesions and multiple sub-diaphragmatic lymph nodes, particularly in the right iliopelvic region (PET-CT of April 27, 2023:  Figure 2A ). Concerning efficacy, the PET-CT after three infusions of Ipi/Nivo (August 9, 2023) revealed a very good metabolic partial response (liver metastases of segment I and IV, right external iliac adenopathy) and a complete response on other liver metastases and other sub-diaphragmatic lymph nodes ( Figure 2B ). PET-CT after three nivolumab maintenance (December 20, 2023) revealed a metabolic complete response in liver and lymph nodes ( Figure 2C ).
case_images: Cerebral MRI, Coronal (A) and axial (B) 3DT1MPRAGE sequences after gadolinium reconstruction showing contrast of the fundus of the internal auditory meatus and of the right geniculate ganglion attesting to right facial neuritis. Hypophisitis is shown in the sagittal sequence (C).
case_images: fimmu-15-1375497-g003.jpg
case_images: PMC10995231_01_fimmu-15-1375497-g003.jpg
case_images: f3
case_images: The cerebral MRI in August 1, 2023 revealed no secondary localization, no signs suggestive of a stroke, but inflammation of the right facial nerve, suggestive of facial nerve neuritis ( Figure 3 ).